Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer

Breast Cancer

Volumn 19, Issue 4, 2012, Pages 309-314

  Tokiniwa, Hideaki ^a   Horiguchi, Jun ^a   Takata, Daisuke ^a   Kikuchi, Mami ^a   Rokutanda, Nana ^a   Nagaoka, Rin ^a   Sato, Ayako ^a   Odawara, Hiroki ^a   Tozuka, Katsunori ^a   Oyama, Tetsunari ^a   Takeyoshi, Izumi ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Breast cancer; Ki 67; Prognostic factor; Topoisomerase IIa

Indexed keywords

ANTHRACYCLINE; DNA TOPOISOMERASE; DNA TOPOISOMERASE 2 ALPHA; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; PROGESTERONE RECEPTOR; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CORRELATION ANALYSIS; EPIDERMAL GROWTH FACTOR TYPE 2 NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; HUMAN TISSUE; LABELING INDEX; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RETROSPECTIVE STUDY; TUMOR GROWTH; TUMOR VOLUME; BREAST TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84874195456     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-011-0291-4     Document Type: Article

References (36)

1. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784-92. (Pubitemid 41549890)
2. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ, 10th St Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133-44. (Pubitemid 47244357)
3. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ, Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20:1319-29.
4. Piccart MJ, Di Leo A, Hamilton A. HER2. a 'predictive factor' ready to use in the daily management of breast cancer patients? Eur J Cancer. 2000;36:1755-61. (Pubitemid 30639494)
5. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol. 2001;19:2334-56. (Pubitemid 32366985)
6. Järvinen TA, Tanner M, Rantanen V, Bärlund M, Borg A, Grénman S, et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol. 2000;156:839-47. (Pubitemid 30626942)
7. Tan KB, Dorman TE, Falls KM, Chung TDY, Mirabelli CK, Crooke ST, et al. Topoisomerase II alpha and topoisomerase II beta differentially spliced forms of topoisomerase II alpha mRNA. Nucleic Acids Res. 1993;21:3719-23.
8. Withoff S, De Jong S, De Vries EGE, Mulder NH. Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance. Anticancer Res. 1996;16:1867-80. (Pubitemid 26270698)
9. Chung DU, Drake SH, Tan KB, Per SR, Crooke ST, Mirabelli CK. Characterization and immunological identification of cDNA clones encoding to human topoisomerase isozymes. Proc Natl Acad Sci USA. 1989;86:9431-5. (Pubitemid 20010440)
10. Roca J, Wang JC. DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism. Cell. 1994;77:609-16. (Pubitemid 24154000)
11. Osheroff N. Biochemical basis for the interactions of type I and type II topoisomerase with DNA. Pharmacol Ther. 1989;41:223-41. (Pubitemid 19069663)
12. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31:13-20. (Pubitemid 13179545)
13. Cattoretti G, Becker MH, Key G, Duchrow M, Schlüter C, Galle J, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992;168:357-63. (Pubitemid 23013251)
14. Umemura S, Komaki K, Noguchi S, Shiba E, Toi M, Kimijima I, et al. Prognostic factors for node-negative breast cancers: results of a study program by the Japanese Breast Cancer Society. Breast Cancer. 1998;5:243-9.
15. Railo M, Nordling S, von Boguslawsky K, Leivonen M, Kyllönen L, von Smitten K. Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer. 1993;68:579-83. (Pubitemid 23258465)
16. Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Matsuoka Y, et al. An evaluation of predictive factors involved in clinical or pathological response to primary chemotherapy in advanced breast cancer. Breast Cancer. 2002;9:145-52.
17. Giuseppe Viale, Anita Giobbie-Hurder, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 2008;26:5569-75.
18. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, et al. Prognostic value of Ki-67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99:167-70.
19. Nishimura R, Osako T, Okumura Y, Hayashi M, Arima N. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Breast Cancer. 2010;17:269-75.
20. Kurosumi M, Suemasu K, Tabei T, Inoue K, Matsumoto H, Sugamata N, et al. Relationship between existence of lymphatic invasion in peritumoral breast tissue and presence of axillary lymph node metastasis in invasive ductal carcinoma of the breast. Oncol Rep. 2001;8:1051-5. (Pubitemid 33758168)
21. Di Leo A, Larsimont D, Gancberg D, Jarvinen T, Beauduin M, Vindevoghel A, et al. HER-2 and topo-isomerase Ha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol. 2001;12:1081-9. (Pubitemid 32834488)
22. Cardoso F, Durbecq V, Larsimont D, Paensmans M, Leroy J, Rouas G et al. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-α gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol. 2004;24:201-9.
23. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ, et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene. 1997;15:537-47. (Pubitemid 27384731)
24. Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, et al. Topoisomerase IIα gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. Breast. 2008;17:506-11.
25. O'Malley FP, Chia S, Tu D, Shepherd L, Levine M, Huntsman D, et al. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer. Breast Cancer Res Treat. 2006;100:S18.
26. Martin-Richard M, Muñoz J, Albanell L, Colomo M, Bellet MJ, Rey J, et al. Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. Oncology. 2004;66:388-94. (Pubitemid 39194361)
27. Zhu L, Li YF, Chen WG, He JR, Peng CH, Zhu ZG, et al. HER2 and topoisomerase IIα: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients. Chin Med J. 2008;121:1965-8.
28. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710-5. (Pubitemid 14035254)
29. Rody A, Karn T, Ruckhäberle, Müller V, Gehrmann M, Solbach C et al. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is prognostic in estrogen receptor (ER) positive breast cancer. Breast Cancer Res Treat. 2009;113:457-66.
30. Lynch BJ, Guinee DG Jr, Holden JA. Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. Hum Pathol. 1997;28:1180-8. (Pubitemid 27446604)
31. Järvinen TA, Kononen J, Pelto-Huikko M, Isola J. Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol. 1996;148:2073-82. (Pubitemid 26170530)
32. Sandri MI, Hochhauser D, Ayton P, Camplejohn RC, Whitehouse R, Turley H, et al. Differential expression of the topoisomerase II alpha and beta genes in human breast cancers. Br J Cancer. 1996;73:1518-24. (Pubitemid 26235376)
33. Järvinen TA, Holli K, Kuukasjarvi T, Isola JJ. Predictive value of topoisomerase II alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer. 1998;77:2267-73. (Pubitemid 28263952)
34. Gómez HL, Pinto JA, Olivera M, Vidaurre T, Doimi FD, Vigil CE, et al. Topoisomerase IIa as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer. Breast. 2011;20(1):39-45.
35. Depowski PL, Rosenthal SI, Brien TP, Stylos S, Johnson RL, Ross JS. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables. Mod Pathol. 2000;13(5):542-7. (Pubitemid 30332106)
36. Schindlbeck C, Mayr D, Olivier C, Rack B, Engelstaedter V, Jueckstock J, et al. Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer. J Cancer Res Clin Oncol. 2010;136(7):1029-37.